Pharma grade
Cannabis-based treatments

MedC undertook the mission of providing cannabis based treatments to a wide range unmet medical needs. We focus exclusively on pharma grade solutions to achieve measurable, controllable and consistent dosage, efficacy and affect across treatments.

About Us

General

MedC Biopharma Corporaion was established by the Drori brothers in 2016 with the sole aim of developing and commercializing Pharma Cannabis related intellectual property.

The company has signed an exclusive joint venture agreement with the world renown Agricultural Research Organization (ARO) which holds one of the world's largest IP repositories in Pharma Cannabis research.

MedC has built a roadmap and intends to bring to market the plethora of ARO solutions for unmet medical needs focusing solely on pharma grade solutions in order to achieve controllable, consistent efficacy and affect across all uses of medical cannabis for general treatments.

About ARO

The National Medical Cannabis Research Center and Gene Bank is at ARO Volcani. MedC has partnered with ARO in the research and development of its treatments.

It is one of the largest and most advanced government backed research centers globally with six institutes specializing in Plant Sciences, Animal Science, Plant Protection, Soil, Water and Environmental Sciences, Agricultural Engineering, and Postharvest and Food Sciences.

Advanced Research

MedC Biopharma employs world renown cannabis biopharma and agriculture experts operating at the highest standards of research and clinical trials facilities.

Team & Advisory

Avi Drori

President & Chairman of the Board

Founder of MedC, serial entrepreneur. Managing Partner at Metro Fresh Ltd (Las Vegas, NV). Former General Manager at Euro Pacific Developers Ltd, Singapore and Papua New Guinea.

Guy Drori

CEO - MedC Israel

Founder of MedC, serial entrepreneur. Managing Partner at Metro Fresh Ltd (Las Vegas, NV). Graduate of Boston University School of Management and LLB from COMAS, Israel. Former US Olympian, Handball Team.

Owen Van Cauwenberghe, Ph.D.

Director

Chief Research Officer at AgMedica Bioscience Inc., founding partner, President and COO of Bio Therapeutic Molecules Inc., Adjunct Associate Professor in the Waterloo School of Pharmacy, former Director at Accucaps Industries Ltd. and former Principal Research Scientist and Director at Eli Lilly Canada.

Dr. Orna Dreazen

Head of Advisory Board

Dr. Orna Dreazen holds a Ph.D. in Biochemistry from theWeizmann Institute of Science and a diploma in Business Administration from the Tel AvivUniversity. Dreazen served in key private and publicindustry positions inestablishments such as Interpharm Laboratories Ltd., PortamanPharmaceuticals Ltd., National PublicHealth Laboratories of the Ministry of Health and IsraelLaboratory Accreditation Authority.

Prof. Hinanit Koltai, Phd

Senior Research Scientist, Agricultural Research Organization, Volcani Center Israel

A full Professor Research Scientist focused on plant derived substances as anti-cancer and anti-inflammatory drugs, plant hormones and plant genomics.

Dr. Shahaf Edut

Advisory Board Member

Postdoctoral Research Fellow at the "The Brain and Behavior Laboratory" University of Haifa, working on PTSD, Pain and Depression models. Phd in Neurobiology, University of Tel Aviv. Senior researcher at Teva Pharmaceuticals (2003-2005).

Prof. Richter-Levin

Advisory Board Member

Founder and head of the Haifa Forum for Brain and Behavior, and the director of the Institute for the Study of Affective Neuroscience (ISAN), Holds PhD in Neurobiology and worked at the Weizmann Institute, was a fellow at the National Institute for Medical Research, London, and now a full professor at the Sagol Department of Neurobiology and the Department of Psychology since 2006.

Dr. Jonas Ekblom

Advisory Board Member

Phd in Pharmacology (Neuro-Pharmacology), based in Los Angeles, active in biotech start-ups with connections to the Cannabis industry in California.

Roy Pelleg

Chief Agronomist

MSc in Agriculture, Hebrew University, Israel. CEO of Growing Smart Ltd an agriculture consultancy firm with vast experience in medical cannabis cultivation in Israel and the US.

Dr. Emmanuel Loeb

Advisory Board Member

A Veterinary Pathologist (DVM), pre-clinical and clinical studies for the development of treatments for pets and animals.  CEO of Patho-Logica, a pre-clinical trials company based in Israel.  

The Problem

While Cannabinoids were found to help in the treatment of numerous medical conditions, the use of the plant in inhaling or digestion of its natural form results in inconsistent and uncontrollable effects.

Each genetic strain of Cannabis and its specific growth conditions create a wide array of variations in cannabinoids concentration, dosage and mix. Patients who rely on medical cannabis for releaf find themselves experiencing inconsistent therapeutic effects.

The need for pharma grade Cannabinoids-baed solutions comes to answer this particular problem for millions of people using medical Cannabis to better their lives.

Products & Roadmap

Our initial product and roadmap addresses conditions that have an immediate demand due to lack of satisfactory solutions with clear benefits to a pharma-grade cannabinoids based solution.

PTSD

Post-traumatic stress disorder is a mental health condition that's triggered by a terrifying event — either experiencing it or witnessing it. Symptoms may include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event.

PTSD affects 40 million sufferers in the US alone with over USD 42 billion in annual costs to the economy.

PSORIASIS

As underlying cells reach the skin's surface and die, their sheer volume causes raised, red plaques covered with white scales. Psoriasis typically occurs on the knees, elbows, and scalp, and it can also affect the torso, palms, and soles of the feet.

It is a USD 13 Billion per annum pharmaceutical market affecting 2% - 4% of the western world.

CTCL (SKIN CANCER)

Cutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas (which are generally B cell related),CTCL is caused by a mutation of T cells.

It is a USD 9 Billion per annum pharmaceutical market worldwide with significant global affect.

News

Dec 17, 2018, 09:00 ET

Volcani Center Announces Significant Breakthroughs in CTCL Skin Cancer Cannabis Treatment Development in Cooperation With MedC Biopharma Corporation of Canada

RISHON LE-ZION, Israel, December 17, 2018 /PRNewswire/ --Volcani Center announces today its preparation of patents for the treatment of Cutaneous T cell lymphoma (CTCL), a class of non-Hodgkin lymphoma - a cancer of the immune system.

CTCL is classified by the FDA as an Orphan Disease, and as such products developed for this disease have the potential to achieve orphan status designation which can accelerate licensing and create a seven-year exclusivity window.

Headed by Professor Hinanit Koltai, the patents are based on a unique formulation of active compounds selectively extracted from the cannabis plant, which have highly cytotoxic activity against malignant T-cell lines.

Further development and distribution are via an exclusive global licensing agreement signed by the ARO via Kidum with cannabis pharmaceutical company MedC Biopharma Corporation of Canada, which has invested in the development of CTCL treatments at ARO to secure the exclusive global license for the CTCL patents, a significant milestone in its efforts to further its aims to become the largest repository of IP in the Pharma Cannabinoids arena.  

MedC's investors include one of Canada's leading LP & pharmaceutical cannabis company, AgMedica Bioscience.

MedC has also forged a partnership with Nextage Innovation (a subsidiary of Nextar Chempharma Solutions) Israel, As MedC's exclusive partner for the development of cannabis-based Rx products including for the development of the CTCL treatments.

Located at the Volcani Center, near Tel-Aviv, ARO is the country's leading cannabis research powerhouse with a repository of IP developed by a team of scientists, whose research has identified multiple effective compositions of cannabinoids and terpenes in the past years.

Clinical trials for a cannabis-based medication developed specifically for CTCL are planned to begin in the beginning of 2019.

Professor Hinanit Koltai, at Volcani Center, said, "We are delighted that our collaborative efforts with MedC will provide them with the IP that will help pave the way in treating CTCL."

Avi Drori, Chairman of MedC Corp (Canada), said, "We are pleased that our investments in the development of cannabis-based medication for CTCL has matured into breakthrough discoveries and resulting patents. We look forward to commencing clinical trials, so we can finally bring hope to patients world-wide seeking a cure for this terrible disease".  

About Cutaneous T-Cell LymphomaCutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. CTCL is caused by a mutation of T cells. The cancerous T cells in the body initially migrate to the skin, causing various lesions to appear.

About ARO Volcani Located agriculture campus in Rishon Letzion, near Tel-Aviv, Volcani Center's six institutes are responsible for Plant Sciences, Animal Science, Plant Protection, Soil, Water and Environmental Sciences, Agricultural Engineering, and Postharvest and Food Sciences. ARO also operates four research stations, in various parts of the country, and serves as a testing center for agricultural produce and equipment.

About MedC Bio Corporation of Canada MedC Biopharma Corporation of Canada was established by the Drori brothers in 2016 with the sole aim of developing and commercializing Pharma Cannabis related intellectual property.  The company has signed an exclusive licensing agreement with world renown National Medical Cannabis Research Lab at Agricultural Research Organization (ARO) Volcani, State of Israel.

As seen on

Contact Us

Please fill in the below form and we will do our best to return your message within 24 hours. Thanks.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again later.